Cosciens Biopharma
(OTC) AEZS
Cosciens Biopharma Financials at a Glance
Market Cap
N/A
Revenue (TTM)
$2.47M
Net Income (TTM)
$5.24M
EPS (TTM)
N/A
P/E Ratio
N/A
Dividend
N/A
Beta (Volatility)
N/A
Dividend
N/A
Beta (Volatility)
N/A
Price
N/A
Volume
N/A
Open
N/A
Price
N/A
Volume
N/A
Open
N/A
Previous Close
N/A
Daily Range
N/A
52-Week Range
N/A
Dividend
N/A
Beta (Volatility)
N/A
Price
N/A
Volume
N/A
Open
N/A
Previous Close
N/A
Daily Range
N/A
52-Week Range
N/A
AEZS News
Aeterna Zentaris Names New CEO
This Week in Biotech
This Week in Biotech
Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Cosciens Biopharma
Industry
Biotechnology
Sector
Health CareEmployees
28
CEO
Peter Harry Puccetti, CFA
Website
www.cosciensbio.comHeadquarters
Summerville, SC 29486, US
AEZS Financials
Key Financial Metrics (TTM)
Gross Margin
33%
Operating Margin
-1%
Net Income Margin
-1%
Return on Equity
-2%
Return on Capital
-48%
Return on Assets
-38%
Earnings Yield
N/A
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
N/A
Shares Outstanding
N/A
Volume
N/A
Short Interest
N/A
Avg. Volume
N/A
Financials (TTM)
Gross Profit
$4.18M
Operating Income
$18.34M
EBITDA
$2.89M
Operating Cash Flow
$17.43M
Capital Expenditure
$19.35K
Free Cash Flow
$17.45M
Cash & ST Invst.
$6.67M
Total Debt
$3.39M
Cosciens Biopharma Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$2.34M
+4.1%
Gross Profit
$819.00K
-61.1%
Gross Margin
35.04%
N/A
Market Cap
N/A
N/A
Market Cap/Employee
N/A
N/A
Employees
12
N/A
Net Income
$1.42M
+43.5%
EBITDA
$3.27M
-218.5%
Quarterly Fundamentals
Net Cash
$26.12M
-37.8%
Accounts Receivable
$1.35M
+38.9%
Inventory
$3.06M
+3184.9%
Long Term Debt
$1.28M
-58.7%
Short Term Debt
$407.00K
+39.6%
Return on Assets
-38.18%
N/A
Return on Invested Capital
-47.57%
N/A
Free Cash Flow
$1.55M
+64.0%
Operating Cash Flow
$1.39M
+67.6%